{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:12:33Z","timestamp":1778616753087,"version":"3.51.4"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04151-1","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T17:10:40Z","timestamp":1764349840000},"page":"1501-1515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Emerging therapeutic strategies for CD30-positive lymphomas"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3374-0238","authenticated-orcid":false,"given":"Alberto","family":"Boretti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"4151_CR1","doi-asserted-by":"crossref","unstructured":"Advani, R.H., Moskowitz, A.J., Bartlett, N.L., Vose, J.M., Ramchandren, R., Feldman, T.A., LaCasce, A.S., Christian, B.A., Ansell, S.M., Moskowitz, C.H. and Brown, L., 2021. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood, The Journal of the American Society of Hematology, 138(6), pp.427-438.","DOI":"10.1182\/blood.2020009178"},{"key":"4151_CR2","doi-asserted-by":"publisher","first-page":"1203471","DOI":"10.3389\/fimmu.2023.1203471","volume":"14","author":"JE Agrusa","year":"2023","unstructured":"Agrusa JE, Egress ER, Lowe EJ. Brentuximab vedotin use in pediatric anaplastic large cell lymphoma. Front Immunol. 2023;14:1203471.","journal-title":"Front Immunol"},{"key":"4151_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2025.101271","author":"MN Alibrahim","year":"2025","unstructured":"Alibrahim MN, Gloghini A, Carbone A. Classic Hodgkin lymphoma: pathobiological features that impact emerging therapies. Blood Rev. 2025. https:\/\/doi.org\/10.1016\/j.blre.2025.101271.","journal-title":"Blood Rev"},{"key":"4151_CR4","first-page":"1","volume":"23","author":"ID Barrera Ch\u00e1vez","year":"2025","unstructured":"Barrera Ch\u00e1vez ID, Viloria \u00c1lvarez JC, Zendejas S\u00e1nchez V, Garc\u00eda-L\u00f3pez JC, Reynoso G\u00f3mez V, Garc\u00eda Rivera D, et al. Efficacy of brentuximab-vedotin combined with PD-1 inhibitors in relapsed\/refractory hodgkin lymphoma with ASCT Consolidation and maintenance therapy: a phase 2 clinical trial. Indian J Hematol Blood Transfusion. 2025;23:1\u20137.","journal-title":"Indian J Hematol Blood Transfusion"},{"key":"4151_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1182\/blood-2020-138849","volume":"136","author":"SK Barta","year":"2020","unstructured":"Barta SK, Feldman TA, DeSimone JA, Kim E, Devajaran K, Wiest D, et al. A phase I trial assessing the feasibility of romidepsin combined with brentuximab vedotin for patients requiring systemic therapy for cutaneous T-cell lymphoma. Blood. 2020;136:24\u20135.","journal-title":"Blood"},{"issue":"Supplement 1","key":"4151_CR6","doi-asserted-by":"publisher","first-page":"6543","DOI":"10.1182\/blood-2022-157201","volume":"140","author":"SK Barta","year":"2022","unstructured":"Barta SK, Feldman TA, DeSimone JA, Kim E, Devajaran K, Yang Y, et al. A phase I trial assessing the feasibility of romidepsin combined with brentuximab vedotin for patients requiring systemic therapy for cutaneous T-cell lymphoma. Blood. 2022;140(Supplement 1):6543\u20134.","journal-title":"Blood"},{"issue":"2","key":"4151_CR7","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.clml.2023.10.001","volume":"24","author":"SK Barta","year":"2024","unstructured":"Barta SK, Liu N, DerSarkissian M, Chen Y, Knowles S, Yu KS, et al. Real-world treatment patterns and clinical outcomes with brentuximab vedotin or other standard therapies in patients with previously treated cutaneous T-cell lymphoma in the United States. Clin Lymphoma Myeloma Leuk. 2024;24(2):e21-e32.e4.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"4151_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101830","volume":"16","author":"C Benevolo Savelli","year":"2024","unstructured":"Benevolo Savelli C, Bisio M, Legato L, Pastore F, Vari R, Ghiani M, et al. Advances in Hodgkin lymphoma treatment: from molecular biology to clinical practice. Cancers. 2024;16(10):1830.","journal-title":"Cancers"},{"issue":"1","key":"4151_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17010094","volume":"17","author":"M Bisio","year":"2025","unstructured":"Bisio M, Legato L, Fasano F, Vari R, Ghiani M, Pastore F, et al. Bispecific antibodies for lymphoid malignancy treatment. Cancers. 2025;17(1):94.","journal-title":"Cancers"},{"issue":"3","key":"4151_CR10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0305-7372(74)80001-0","volume":"1","author":"G Bonadonna","year":"1974","unstructured":"Bonadonna G, Monfardini S. Chemotherapy of non-Hodgkin\u2019s lymphomas. Cancer Treat Rev. 1974;1(3):167\u201381.","journal-title":"Cancer Treat Rev"},{"key":"4151_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176618","author":"A Boretti","year":"2024","unstructured":"Boretti A. Improving chimeric antigen receptor T-cell therapies by using artificial intelligence and internet of things technologies: a narrative review. Eur J Pharmacol. 2024. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176618.","journal-title":"Eur J Pharmacol"},{"key":"4151_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2024.109137","volume":"182","author":"A Boretti","year":"2024","unstructured":"Boretti A. The transformative potential of AI-driven CRISPR-Cas9 genome editing to enhance CAR T-cell therapy. Comput Biol Med. 2024;182:109137.","journal-title":"Comput Biol Med"},{"issue":"5","key":"4151_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/CCO.0000000000001071","volume":"36","author":"PJ Br\u00f6ckelmann","year":"2024","unstructured":"Br\u00f6ckelmann PJ. Treatment approaches for older Hodgkin lymphoma patients. Curr Opin Oncol. 2024;36(5):353\u20139.","journal-title":"Curr Opin Oncol"},{"issue":"2\u20133","key":"4151_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s44228-023-00038-6","volume":"5","author":"G Caddeo","year":"2023","unstructured":"Caddeo G, Tecchio C, Chinello M, Bortoluzzi S, Sandon S, Gasparella L, et al. Refractory anaplastic large cell lymphoma rescued by the combination of the second-generation ALK inhibitor Brigatinib, high-dose chemotherapy and allogeneic stem cell transplantation: a case report and review of the literature. Clin Hematol Int. 2023;5(2\u20133):130\u20138.","journal-title":"Clin Hematol Int"},{"issue":"1","key":"4151_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11899-024-00746-7","volume":"20","author":"KB Case","year":"2025","unstructured":"Case KB, Allen PB. Advances in novel systemic therapies for the management of cutaneous T cell lymphoma (CTCL). Curr Hematol Malign Rep. 2025;20(1):5.","journal-title":"Curr Hematol Malign Rep"},{"issue":"4","key":"4151_CR16","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/s41375-021-01191-8","volume":"35","author":"D Chihara","year":"2021","unstructured":"Chihara D, Miljkovic M, Iyer SP, Vega F. Targeted based therapy in nodal T-cell lymphomas. Leukemia. 2021;35(4):956\u201367.","journal-title":"Leukemia"},{"key":"4151_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-020-0866-3","volume":"22","author":"Y Choi","year":"2020","unstructured":"Choi Y, Diefenbach CS. Advances in therapy for relapsed or refractory Hodgkin lymphoma. Curr Oncol Rep. 2020;22:1\u20138.","journal-title":"Curr Oncol Rep"},{"key":"4151_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-8722-7-11","volume":"7","author":"B Coiffier","year":"2014","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014;7:1\u20139.","journal-title":"J Hematol Oncol"},{"key":"4151_CR19","doi-asserted-by":"publisher","first-page":"S862","DOI":"10.1016\/j.annonc.2021.08.1413","volume":"32","author":"CL Cowey","year":"2021","unstructured":"Cowey CL, Fiorillo JA, Larson T, Waterhouse DM, Chaney MF, Knowles S. 1029TiP phase II trial of pembrolizumab (pembro) and brentuximab vedotin (BV) in patients with metastatic solid malignancies after progression on prior programmed cell death protein (PD)-1 inhibitors (SGN35-033). Ann Oncol. 2021;32:S862.","journal-title":"Ann Oncol"},{"issue":"3","key":"4151_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00428-024-03832-6","volume":"485","author":"GA Croci","year":"2024","unstructured":"Croci GA, Appio L, Cecchetti C, Losi L, Pedrazzi G, Corti B, et al. Primary cutaneous, epidermotropic mycosis fungoides-like presentation: critical appraisal and description of two novel cases, broadening the spectrum of ALK+ T-cell lymphoma. Virchows Arch. 2024;485(3):417\u201325.","journal-title":"Virchows Arch"},{"issue":"1","key":"4151_CR21","volume":"2016","author":"W Delacruz","year":"2016","unstructured":"Delacruz W, Setlik R, Hassantoufighi A, Daya S, Cooper S, Selby D, et al. Novel Brentuximab Vedotin combination therapies show promising activity in highly refractory CD30+ Non\u2010Hodgkin lymphoma: a case series and review of the literature. Case Rep Oncol Med. 2016;2016(1):2596423.","journal-title":"Case Rep Oncol Med"},{"key":"4151_CR22","unstructured":"Department of Health and Aged Care. Minister for health and aged care\u2014interview on 3AW mornings\u201430 May 2023. 2023. https:\/\/www.health.gov.au\/ministers\/the-hon-mark-butler-mp\/media\/minister-for-health-and-aged-care-interview-on-3aw-mornings-30-may-2023."},{"key":"4151_CR23","first-page":"27","volume":"37","author":"R Dulery","year":"2025","unstructured":"Dulery R, Guiraud V, Choquet S, Garnache-Ottou F, Ledoux C, et al. T cell malignancies after CAR T cell therapy in the DESCAR-T registry. Nat Med. 2025;37:27.","journal-title":"Nat Med"},{"issue":"14","key":"4151_CR24","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","volume":"328","author":"RI Fisher","year":"1993","unstructured":"Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;328(14):1002\u20136.","journal-title":"N Engl J Med"},{"issue":"4","key":"4151_CR25","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","volume":"102","author":"JA Francisco","year":"2003","unstructured":"Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30\u2014monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458\u201365.","journal-title":"Blood"},{"issue":"11","key":"4151_CR26","first-page":"1097","volume":"62","author":"H Gao","year":"2024","unstructured":"Gao H, Li Y, Li N, Wei W, Dong R, Wang T, et al. Clinical study of immune-targeting combined with attenuated chemotherapy in the treatment of children with classic Hodgkin lymphoma | \u514d\u75ab\u9776\u5411\u8054\u5408\u51cf\u6bd2\u5316\u7597\u6cbb\u7597\u513f\u7ae5\u7ecf\u5178\u970d\u5947\u91d1\u6dcb\u5df4\u7624\u7684\u4e34\u5e8a\u7814\u7a76. Zhonghua Er Ke Za Zhi. 2024;62(11):1097\u2013102.","journal-title":"Zhonghua Er Ke Za Zhi"},{"issue":"10214","key":"4151_CR27","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1016\/S0140-6736(19)32527-9","volume":"394","author":"PJ Garc\u00eda","year":"2019","unstructured":"Garc\u00eda PJ. Corruption in global health: the open secret. Lancet. 2019;394(10214):2119\u201324.","journal-title":"Lancet"},{"issue":"7","key":"4151_CR28","volume":"5","author":"C Gentille","year":"2022","unstructured":"Gentille C, Sarfraz H, Joshi J, Randhawa J, Shah S, Pingali SR. Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed\/refractory peripheral T\u2010cell lymphoma. Cancer Rep. 2022;5(7):e1581.","journal-title":"Cancer Rep"},{"key":"4151_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1360275","volume":"15","author":"F Giannotti","year":"2024","unstructured":"Giannotti F, De Ramon Ortiz C, Simonetta F, Nguyen TH, Dirren Berger L, Duchosal MA, et al. Remission of relapsed\/refractory classical Hodgkin lymphoma induced by brentuximab vedotin and pembrolizumab combination after allogeneic hematopoietic stem cell transplantation: a case report. Front Immunol. 2024;15:1360275.","journal-title":"Front Immunol"},{"key":"4151_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.910073","volume":"10","author":"EH Glynn","year":"2022","unstructured":"Glynn EH. Corruption in the health sector: a problem in need of a systems-thinking approach. Front Public Health. 2022;10:910073.","journal-title":"Front Public Health"},{"issue":"3","key":"4151_CR31","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.bbmt.2018.12.149","volume":"25","author":"NS Grover","year":"2019","unstructured":"Grover NS, Park SI, Ivanova A, Eldridge P, McKay K, Cheng C, et al. A phase Ib\/II study of anti-CD30 chimeric antigen receptor T cells for relapsed\/refractory CD30+ lymphomas. Biol Blood Marrow Transplant. 2019;25(3):S66.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"4151_CR32","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.196899","volume":"104","author":"A Hagenbeek","year":"2019","unstructured":"Hagenbeek A, Mooij H, Zijlstra J, Lugtenburg P, van Imhoff G, Nijland M, et al. Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed\/refractory classical Hodgkin lymphoma: the HOVON\/LLPC transplant brave study. Haematologica. 2019;104(4):e151.","journal-title":"Haematologica"},{"key":"4151_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.585830","volume":"10","author":"DC Harrer","year":"2020","unstructured":"Harrer DC, Menhart K, Mayer S, Schmidt B, Dettmer MS, Hartmann S, et al. Unusual late relapse of ALK-positive anaplastic large cell lymphoma successfully cleared using the ALK-inhibitor crizotinib: case report. Front Oncol. 2020;10:585830.","journal-title":"Front Oncol"},{"key":"4151_CR34","volume":"23","author":"G Hasegawa","year":"2025","unstructured":"Hasegawa G, Nakagawa N, Ueda Y, Yamazaki M. Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomas. Leuk Res Rep. 2025;23:100500.","journal-title":"Leuk Res Rep"},{"key":"4151_CR35","doi-asserted-by":"crossref","unstructured":"Herrera, A.F., Moskowitz, A.J., Bartlett, N.L., Vose, J.M., Ramchandren, R., Feldman, T.A., LaCasce, A.S., Ansell, S.M., Moskowitz, C.H., Fenton, K. and Ogden, C.A., 2018. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood, The Journal of the American Society of Hematology, 131(11), pp.1183-1194.","DOI":"10.1182\/blood-2017-10-811224"},{"issue":"10168","key":"4151_CR36","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229\u201340.","journal-title":"Lancet"},{"issue":"3","key":"4151_CR37","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","volume":"33","author":"S Horwitz","year":"2022","unstructured":"Horwitz S, O\u2019connor OA, Pro B, Tr\u00fcmper L, Iyer S, Advani R, et al. The ECHELON-2 trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022;33(3):288\u201398.","journal-title":"Ann Oncol"},{"key":"4151_CR38","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1182\/blood-2021-153968","volume":"138","author":"GE Hucks Jr","year":"2021","unstructured":"Hucks GE Jr, Savoldo B, Dotti G, Cheng CJA, Babinec C, Kasow KA, et al. CD30-Directed chimeric antigen receptor (CAR)-T cells for treatment of Hodgkin lymphoma and non-Hodgkin lymphoma in pediatric patients. Blood. 2021;138:2829.","journal-title":"Blood"},{"key":"4151_CR39","doi-asserted-by":"crossref","unstructured":"Hutchison RE. Therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALK+ALCL. In: Therapeutic strategies to overcome ALK resistance in cancer; 2021. pp. 141\u2013159.","DOI":"10.1016\/B978-0-12-821774-0.00012-7"},{"issue":"3","key":"4151_CR40","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3390\/cancers17030496","volume":"17","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Dong S, Wang Y. Antibody-drug conjugates targeting CD30 in T-cell lymphomas: clinical progression and mechanism. Cancers. 2025;17(3):496.","journal-title":"Cancers"},{"issue":"3","key":"4151_CR41","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1159\/000511111","volume":"13","author":"T Jo","year":"2020","unstructured":"Jo T, Sakai T, Matsuzaka K, Nakagawa M, Miyoshi H, Utsumi T, et al. Successful treatment of a patient with brentuximab vedotin-refractory ALK-negative anaplastic large cell lymphoma with romidepsin. Case Rep Oncol. 2020;13(3):1402\u20139.","journal-title":"Case Rep Oncol"},{"issue":"9","key":"4151_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.149","volume":"8","author":"J de Kanter","year":"2024","unstructured":"de Kanter J, Steemers A, Gonzalez D, Verduin L, Bongaers M, van Boxtel R, et al. Single-cell RNA sequencing of pediatric Hodgkin lymphoma to study the inhibition of T cell subtypes. HemaSphere. 2024;8(9):e149.","journal-title":"HemaSphere"},{"issue":"20","key":"4151_CR43","doi-asserted-by":"publisher","first-page":"6428","DOI":"10.1158\/1078-0432.CCR-11-0488","volume":"17","author":"J Katz","year":"2011","unstructured":"Katz J, Janik JE, Younes A. Brentuximab vedotin (SGN-35). Clin Cancer Res. 2011;17(20):6428\u201336.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4151_CR44","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3324\/haematol.2019.243238","volume":"106","author":"MJ Kersten","year":"2021","unstructured":"Kersten MJ, Driessen J, Zijlstra JM, Plattel WJ, Morschhauser F, Lugtenburg PJ, et al. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON\/LLPC transplant brave study. Haematologica. 2021;106(4):1129.","journal-title":"Haematologica"},{"issue":"1","key":"4151_CR45","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1158\/1078-0432.CCR-24-1913","volume":"31","author":"WS Kim","year":"2025","unstructured":"Kim WS, Shortt J, Zinzani PL, Goebeler ME, Opat S, Ramchandren R, et al. A phase II study of acimtamig (AFM13) in patients with CD30-positive, relapsed, or refractory peripheral T-cell lymphomas. Clin Cancer Res. 2025;31(1):65\u201373.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"4151_CR46","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1016\/j.ymthe.2024.06.037","volume":"32","author":"L Kua","year":"2024","unstructured":"Kua L, Ng CH, Tan JW, Zhou L, Tan SY, Lee SL, et al. Novel OX40 and 4-1BB derived spacers enhance CD30 CAR activity and safety in CD30 positive lymphoma models. Mol Ther. 2024;32(10):3504\u201321.","journal-title":"Mol Ther"},{"key":"4151_CR47","doi-asserted-by":"crossref","unstructured":"Maakaron, J.E., Hu, M. and El Jurdi, N., 2022. Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations. Bmj, 378.","DOI":"10.1136\/bmj-2021-068956"},{"issue":"11","key":"4151_CR48","first-page":"12206","volume":"13","author":"H Ma","year":"2021","unstructured":"Ma H, Li X, Lin M, Lv K, Zhang M, Wu X. Advances in CD30-and PD-1-targeted therapies for relapsed or refractory Hodgkin lymphoma. Am J Transl Res. 2021;13(11):12206.","journal-title":"Am J Transl Res"},{"issue":"8","key":"4151_CR49","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.clml.2024.03.013","volume":"24","author":"M Mei","year":"2024","unstructured":"Mei M, Tsai N-C, Palmer J, Popplewell L, Siddiqi T, Chen R, et al. Brentuximab vedotin plus ibrutinib in relapsed and refractory Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2024;24(8):537\u201342.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"4151_CR50","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12885-024-13400-5","volume":"25","author":"F Meng","year":"2025","unstructured":"Meng F, Xiang M, Liu Y, Zeng D. Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed\/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis. BMC Cancer. 2025;25(1):78.","journal-title":"BMC Cancer"},{"issue":"1","key":"4151_CR51","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1182\/hematology.2022000365","volume":"2022","author":"AJ Moskowitz","year":"2022","unstructured":"Moskowitz AJ. Do all patients with primary refractory\/first relapse of HL need autologous stem cell transplant? Hematology. 2022;2022(1):699\u2013705.","journal-title":"Hematology"},{"issue":"18","key":"4151_CR52","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1182\/blood.2023021789","volume":"144","author":"AJ Moskowitz","year":"2024","unstructured":"Moskowitz AJ, Stuver RN, Horwitz SM. Current and upcoming treatment approaches to common subtypes of PTCL (PTCL, NOS; ALCL; and TFHs). Blood. 2024;144(18):1887\u201397.","journal-title":"Blood"},{"issue":"9","key":"4151_CR53","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1097\/PAS.0000000000002268","volume":"48","author":"S Narala","year":"2024","unstructured":"Narala S, Saleem A, Brown RA, Kim J, Nagarajan P, Hernandez-Machain V, et al. Histopathologic and clinical characterization of brentuximab vedotin-associated rash. Am J Surg Pathol. 2024;48(9):1131\u20137.","journal-title":"Am J Surg Pathol"},{"issue":"18","key":"4151_CR54","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1182\/blood.2024024487","volume":"144","author":"J Nie","year":"2024","unstructured":"Nie J, Wang C, Zheng L, Zhang Y, Yao Y, Zhao N, et al. Epigenetic agents plus anti-PD-1 reprogram the tumor microenvironment and restore antitumor efficacy in Hodgkin lymphoma. Blood. 2024;144(18):1936\u201350.","journal-title":"Blood"},{"issue":"1","key":"4151_CR55","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1182\/hematology.2024000530","volume":"2024","author":"IA Nizamuddin","year":"2024","unstructured":"Nizamuddin IA, Mehta-Shah N. BV and beyond: how to incorporate novel agents into PTCL management. Hematology. 2024;2024(1):54\u201361.","journal-title":"Hematology"},{"issue":"24","key":"4151_CR56","doi-asserted-by":"publisher","first-page":"5733","DOI":"10.3390\/cancers15245733","volume":"15","author":"K Noguchi","year":"2023","unstructured":"Noguchi K, Ikawa Y. Strategy for pediatric patients with relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: a review. Cancers. 2023;15(24):5733.","journal-title":"Cancers"},{"key":"4151_CR57","doi-asserted-by":"crossref","unstructured":"O'Connor, O.A., Lue, J.K., Sawas, A., Amengual, J.E., Deng, C., Kalac, M., Falchi, L., Marchi, E., Turenne, I., Lichtenstein, R. and Rojas, C., 2018. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1\u20132 trial. The Lancet Oncology, 19(2), pp.257-266.","DOI":"10.1016\/S1470-2045(17)30912-9"},{"issue":"3","key":"4151_CR58","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/ajh.27165","volume":"99","author":"SY Ong","year":"2024","unstructured":"Ong SY, Zain JM. Aggressive T-cell lymphomas: 2024: updates on diagnosis, risk stratification, and management. Am J Hematol. 2024;99(3):439\u201356.","journal-title":"Am J Hematol"},{"key":"4151_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2024.07.007","author":"A Pavlovsky","year":"2024","unstructured":"Pavlovsky A, Altuve JIG, Cerutti A, Fiad L, Kurgansky N, Warley F, et al. Benefits of BV-AVD (brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine) in patients with advanced-stage Hodgkin\u2019s lymphoma: an analysis of the ECHELON 1 trial by the GATLA group using the Delphi Method. Hematology Transfusion Cell Therapy. 2024. https:\/\/doi.org\/10.1016\/j.htct.2024.07.007.","journal-title":"Hematology Transfusion Cell Therapy"},{"key":"4151_CR60","unstructured":"Prince, H.M., Kim, Y.H., Horwitz, S.M., Dummer, R., Scarisbrick, J., Quaglino, P., Zinzani, P.L., Wolter, P., Sanches, J.A., Ortiz- Romero, P.L. and Akilov, O.E., 2017. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. The Lancet, 390(10094), pp.555-566."},{"key":"4151_CR61","doi-asserted-by":"crossref","unstructured":"Pro, B., Advani, R., Brice, P., Bartlett, N.L., Rosenblatt, J.D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M., Connors, J.M. and Yang, Y., 2012. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. Journal of clinical oncology, 30(18), pp.2190-2196.","DOI":"10.1200\/JCO.2011.38.0402"},{"issue":"32","key":"4151_CR62","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1200\/JCO.20.01342","volume":"38","author":"CA Ramos","year":"2020","unstructured":"Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2020;38(32):3794\u2013804.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4151_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2023.101444","volume":"36","author":"C Rigaud","year":"2023","unstructured":"Rigaud C, Kn\u00f6rr F, Brugi\u00e8res L, Woessmann W. Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents. Best Pract Res Clin Haematol. 2023;36(1):101444.","journal-title":"Best Pract Res Clin Haematol"},{"key":"4151_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.858021","volume":"13","author":"W Sang","year":"2022","unstructured":"Sang W, Wang X, Geng H, Li T, Li D, Zhang B, et al. Anti-PD-1 therapy enhances the efficacy of CD30-directed chimeric antigen receptor T cell therapy in patients with relapsed\/refractory CD30+ lymphoma. Front Immunol. 2022;13:858021.","journal-title":"Front Immunol"},{"issue":"5","key":"4151_CR65","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.3390\/curroncol31050195","volume":"31","author":"D Sano","year":"2024","unstructured":"Sano D, Liu N, Knowles S, Yu KS, Lee ST. Brentuximab vedotin retreatment in patients with relapsed or refractory classical Hodgkin lymphoma or peripheral T-cell lymphoma: a retrospective United States claims analysis. Curr Oncol. 2024;31(5):2598\u2013609.","journal-title":"Curr Oncol"},{"issue":"1","key":"4151_CR66","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1182\/hematology.2024000668","volume":"2024","author":"JG Schroers-Martin","year":"2024","unstructured":"Schroers-Martin JG, Advani R. When should we use it? The role of brentuximab vedotin in 2024. Hematology. 2024;2024(1):511\u20136.","journal-title":"Hematology"},{"issue":"15","key":"4151_CR67","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1182\/blood-2017-09-772673","volume":"131","author":"GL Shah","year":"2018","unstructured":"Shah GL, Moskowitz CH. Transplant strategies in relapsed\/refractory Hodgkin lymphoma. Blood. 2018;131(15):1689\u201397.","journal-title":"Blood"},{"key":"4151_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/frma.2021.614013","volume":"6","author":"S Sismondo","year":"2021","unstructured":"Sismondo S. Epistemic corruption, the pharmaceutical industry, and the body of medical science. Front Res Metr Analyt. 2021;6:614013.","journal-title":"Front Res Metr Analyt"},{"key":"4151_CR69","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/blood-2020-136917","volume":"136","author":"V Stefoni","year":"2020","unstructured":"Stefoni V, Corradini P, Orsucci L, Volpetti S, Argnani L, Dodero A, et al. Brentuximab vedotin as single agent in the treatment of relapsed\/refractory CD30 positive peripheral T-cell lymphoma patients: a phase 2 study of the Fondazione Italiana Linfomi. Blood. 2020;136:21.","journal-title":"Blood"},{"key":"4151_CR70","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2963","author":"V Stefoni","year":"2022","unstructured":"Stefoni V, Pellegrini C, Argnani L, Corradini P, Dodero A, Orsucci L, et al. Brentuximab vedotin in the treatment of relapsed\/refractory CD30+ peripheral T\u2010cell lymphoma: a FIL phase 2 study. Hematol Oncol. 2022. https:\/\/doi.org\/10.1002\/hon.2963.","journal-title":"Hematol Oncol"},{"issue":"12","key":"4151_CR71","first-page":"1607","volume":"44","author":"S Tang","year":"2024","unstructured":"Tang S, Mi J. Clinical advances in antibody\u2013drug conjugates for hematological malignancies | \u6297\u4f53\u836f\u7269\u5076\u8054\u7269\u5728\u8840\u6db2\u80bf\u7624\u4e2d\u7684\u4e34\u5e8a\u5e94\u7528\u7814\u7a76\u8fdb\u5c55. J Shanghai Jiaotong Univ (Med Sci). 2024;44(12):1607\u201314.","journal-title":"J Shanghai Jiaotong Univ (Med Sci)"},{"issue":"10","key":"4151_CR72","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.clml.2024.05.017","volume":"24","author":"SK Thiruvengadam","year":"2024","unstructured":"Thiruvengadam SK, Mei MG, Chen L, Song JY, Poetker M, Nathwani N, et al. Phase I trial of brentuximab vedotin plus cyclosporine in relapsed\/refractory Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2024;24(10):724-731.e1.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"4151_CR73","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00280-023-04609-5","volume":"93","author":"Y Tonozuka","year":"2024","unstructured":"Tonozuka Y, Tanaka H, Nomura K, Yano H, Kuroda J, Soeda J, et al. The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis. Cancer Chemother Pharmacol. 2024;93(2):137\u201349.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"4151_CR74","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/bjh.18841","volume":"201","author":"M Veyri","year":"2023","unstructured":"Veyri M, Spano JP, Le Bras F, Marcelin AG, Todesco E. CD30 as a therapeutic target in adult haematological malignancies: where are we now? Br J Haematol. 2023;201(6):1033\u201346.","journal-title":"Br J Haematol"},{"issue":"5","key":"4151_CR75","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","volume":"23","author":"CM Wang","year":"2017","unstructured":"Wang CM, Wu ZQ, Wang Y, Guo YL, Dai HR, Wang XH, et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial. Clin Cancer Res. 2017;23(5):1156\u201366.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4151_CR76","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10875-024-01723-8","volume":"44","author":"J Wang","year":"2024","unstructured":"Wang J, Zhou M, Zhou J, Xiao M, Huang L. Correction to: Monozygotic twins with MAGT1 deficiency and Epstein\u2013Barr virus-positive classic Hodgkin lymphoma receiving anti-CD30 CAR T-cell immunotherapy: a case report (Journal of Clinical Immunology, (2024), 44, 4, (91), 10.1007\/s10875-024-01690-0). J Clin Immunol. 2024;44(6):135.","journal-title":"J Clin Immunol"},{"issue":"1","key":"4151_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101889","volume":"6","author":"L Wang","year":"2025","unstructured":"Wang L, Wang Y, He X, Cao Q, Zhang Z, Xu S, et al. CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells. Cell Rep Med. 2025;6(1):101889.","journal-title":"Cell Rep Med"},{"issue":"4","key":"4151_CR78","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/ejh.13568","volume":"106","author":"Z Van de Wyngaert","year":"2021","unstructured":"Van de Wyngaert Z, Coppo P, Cervera P, Fabiani B, Lemonnier MP, Corre E, et al. Combination of brentuximab-vedotin and ifosfamide, carboplatin, etoposide in relapsed\/refractory peripheral T-cell lymphoma. Eur J Haematol. 2021;106(4):467\u201372.","journal-title":"Eur J Haematol"},{"issue":"10","key":"4151_CR79","first-page":"520","volume":"22","author":"AC Xavier","year":"2024","unstructured":"Xavier AC, Hochberg J, Cairo MS. Targeted immunotherapy in the treatment of childhood and adolescent classic Hodgkin lymphoma. Clin Adv Hematol Oncol. 2024;22(10):520\u201330.","journal-title":"Clin Adv Hematol Oncol"},{"key":"4151_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107628","volume":"213","author":"B Xia","year":"2025","unstructured":"Xia B, Feng H, Jiang X, Shen Y, Chen Z, Chen Y, et al. Development of chimeric nanobody-granzyme B functionalized ferritin nanoparticles for precise tumor therapy. Pharmacol Res. 2025;213:107628.","journal-title":"Pharmacol Res"},{"issue":"6","key":"4151_CR81","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1158\/2159-8290.CD-20-1209","volume":"11","author":"TA Yap","year":"2021","unstructured":"Yap TA, Parkes EE, Peng W, Moyers JT, Curran MA, Tawbi HA. Development of immunotherapy combination strategies in cancer. Cancer Discov. 2021;11(6):1368\u201397.","journal-title":"Cancer Discov"},{"issue":"1","key":"4151_CR82","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrd3629","volume":"11","author":"A Younes","year":"2012","unstructured":"Younes A, Yasothan U, Kirkpatrick P. Brentuximab vedotin. Nat Rev Drug Discov. 2012;11(1):19.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"4151_CR83","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1002\/ajh.26270","volume":"96","author":"JM Zain","year":"2021","unstructured":"Zain JM, Hanona P. Aggressive T-cell lymphomas: 2021 updates on diagnosis, risk stratification and management. Am J Hematol. 2021;96(8):1027\u201346.","journal-title":"Am J Hematol"},{"issue":"7","key":"4151_CR84","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1007\/s00277-023-05446-5","volume":"103","author":"K Zhou","year":"2024","unstructured":"Zhou K, Gong D, Han Y, Huang W. Role of brentuximab vedotin plus sirolimus in the treatment of classical Hodgkin lymphoma type post-transplant lymphoproliferative disorder: a case-based review. Ann Hematol. 2024;103(7):2207\u201313.","journal-title":"Ann Hematol"},{"issue":"2","key":"4151_CR85","doi-asserted-by":"publisher","first-page":"41","DOI":"10.18620\/ctt-1866-8836-2024-13-2-41-46","volume":"13","author":"JA Zhuravleva","year":"2024","unstructured":"Zhuravleva JA, Fedorova LV, Lepik EE, Ramazanova NM, Borzenkova NM, Mikhailova NB, et al. A clinical case of successful treatment of CD30-negative angioimmunoblastic T-cell lymphoma using brentuximab vedotin and lenalidomide followed by allogeneic hematopoietic stem cell transplantation. Cell Ther Transplant. 2024;13(2):41\u20136.","journal-title":"Cell Ther Transplant"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04151-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04151-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04151-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:03:21Z","timestamp":1776769401000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04151-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":85,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["4151"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04151-1","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"25 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"The author has no conflict of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Generative AI and AI-assisted technologies have been used to improve the language and readability of the paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI and AI-assisted technologies"}}]}}